Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-008: MK-7684A vs Atezolizumab in ES-SCLC
NCT05224141Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
A Phase 3 trial of vibostolimab, pembrolizumab in small cell lung cancer (SCLC), sponsored by Merck & Co.. Started Mar 2022; status: active, not recruiting.
02
Drugs
vibostolimabpembrolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05224141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05224141.